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G amma interferon (IFN-y) , a product o f activated ly m-
phocytes, influences keratinocyte proliferation and differ-
entiatio n . R ecombinant gamma interferon (r-IFN-y) w as 
radioiodinated using the Bolto n-Hunter reagent and re-
tained 90% o f its biologic activity as d etermined b y in-
duction of HLA-DR expression. The biochemical ligand-
binding pro perties of iodinated IFN-y to cultured human 
keratinocytes revealed a plateau of binding at 150 m in at 
4°C, and a single class of specific hig h affll1ity recepto rs 
We have previously studied the interaction of gamma interferon (IFN-y), a produ ct of activated T lym-phocytes, with cultured human keratinocytes and made the following observa tions: (1) Recombi-nant gamma interferon (r-IFN-y) induces the 
synthesis and expression of HLA-DR on keratinocytes [1,2]; (2) 
r-IFN-y inhibits the growth of kera tinocytes in a concentration-
dependent fas hion [3]; (3) r-IFN-y induces ultras tructural changes 
in keratinocytes suggesting an influence on di ffe rentiation [4]; and 
(4) durin g allogeneic mixed lymphocy te reactions, IFN-y is 
produced and may modulate lymphocy te-keratinocyte reactions 
[5]. 
These results indicate that IFN-y can bind to and interact in a 
biologically relevant fas hion with kera tinocy tes. This report will 
characterize the binding of iodinated r-IFN-y C2sI-IFN-y) to cul-
tured human keratinocytes and correlate this binding to its bio-
logic ac tivity. 
MA T ERIALS AND METHO DS 
Cell Culture Single-cell suspensions of norm al skin from face 
lift skin was prepared as previously described [3]. The keratino-
cytes were grown on collagen coated Petri dishes (Lux, Flow 
Laboratories, N aperville, Illinois) with Dulbecco's modifIed Ea-
gle's medium (DMEM) containing 1.4 mm calcium, supple-
mented with 10% heat inactivated fetal calf serum and 2 mm 
glutamine. 
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Abbreviations: 
'BSA: bovine serum albumin 
DMEM: Dulbecco's modified Eagle's medium 
IFN-y: gamma interferon 
125I_IFN_y: iodinated recombinant gamma interferon 
r-IFN-y: recombinant gamma in terferon 
(kD = 1.3 X 10 - 10 M; 2200 sites/cell) . The binding of 
human IFN-y, to k eratinocytes was inhibited by human r-
IFN-y, but not by either murine recombinant gamma in-
terferon o r human recombinant beta interferon (r- IFN-,B). 
The presence o f hig h affinit y receptor sites o n human ke-
ratinocy tes assures the receptio n of appro priate immuno-
logic signals in Iy mphocyte-keratinocy te inte ractions . J In-
vest DeY/natol 89:132- 135, 1987 
Interferons Lyophilized recombinant human and murine IFN-
I' was kindly provided by Dr. Michael Shepard (Genentech, Inc., 
South San Francisco, California). T he specifI c activity of human 
r-IFN-y, purifIed to homogeneity, was 2 x 107 units/mg as de-
termined by virus inhibitition plaque assay . Recombinant human 
beta-ser IFN was kindly provided by Dr. T. Basham (Stanford 
U niversity, Stanfo rd, California). 
1251 Iodination of r -IFN- l' The iodin ation procedure utilized 
was that previously reported by Aiyer et al with slight modifI-
cati on [6]. Briefl y, 500 mC i of dried 12sI-diiodo-Bolton-Hunter 
[7] reagent (4250 Ci/mmol; purchased from Amersham C orp. , 
Arlington Heights, Illinois) was inCLfbated with 10 J.L g of freshly 
reconstituted r-IFN-y in 100 J.LI of 0.1 M sodium borate, pH 8. 5 
on ice for 2 h. The reaction was stopped by the addition of 100 
J.LI of 0.2 M glycine in 0. 1 M sodium borate pH 8. 5. The mixture 
was then placed on Sephadex G25-M column (prepacked, PD-
10 columns fro m Pharmacia, Inc. , Piscataway, N ew Jersey) equi-
librated with 0. 1 M sodium phos phate buffer, pH 7. 5, containing 
0.25% (w/v) gelatin (swine skin, 300 Bloom , purchased from 
Sigma C hemical Co. , St. Louis, Missouri). Fractions (0.5 ml) 
were collected; fractions 6 and 7 contained the greatest amount 
of 125I_IFN_y and were stored at 4°C. Greater than 90% of the 
radioactivity in these fra ctions was precipitable with 10% tri-
chl oroacetic acid (T CA) . T he 12SI-IFN- y obtained by this pro-
cedure had a specifIc activity of 6.6 J.LCil J.L g, based on a molecular 
weight of r-IFN-y of 34,000 daltons. T he iodinated r-IFN- y re-
tained its ability to induce HLA-DR and inhibit the proliferation 
of cultured keratinocytes. The induction of the HLA-DR expres-
sion was studied as below, but the antiproliferative effect (300 
U / ml) was onl y determined by phase microscopy w ithout further 
quantitation. 
Keratinocyte HLA-DR Staining Keratinocyte HLA-DR 
staining was performed as previously described [5] . Briefly, either 
iodinated r-IFN-y or noniodinated r-IFN-y was preincubated with 
keratinocytes at the indicated concentration for 3 days. N ext, the 
keratinocytes were trypsinized (0.3% trypsin , 1 % EDT A) into 
single-cell suspension and indirectly stained using anti-HLA-DR 
(L243; Becton-Dickinson, Mountain View , California) and flu o-
rescein isothiocyanate-conjugated goat anti mouse IgG (Becton-
0022-202X/87/1103.50 Copyright © 1987 by T he Society for Inves tiga tive D ermatology, Inc. 
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Figure 1. Biologic activity of 12sl_IFN_y (ope" circles) compared with 
nonradioactive r-IFN-y (closed circles) as measured by the induction of 
HLA-DR expression on cultured keratinocytes. After 3 days of treatment, 
the kcratinocytes were washed, trypsinized into single cell suspension , 
and indirectly stained with anti-HLA-DR antibodies and viewed by flu-
orescence microscopy. 
Dickinson). The stained cells were made visible and counted with 
an Olympus BH-2 fluorescence microscope . 
Time Course of I2sl _IFN_y Binding to Keratinocytes N ear-
confluent monolayers ofkeratinocytes in 3.5 cm dishes containing 
1-3 X 106 keratinocytes were washed four times with DMEM 
plus 0. 1 % bovine serum albumin (BSA) to remove nonattached 
cells. '25I_IFN_y (175 pmol; 34,000 cpm) was added in the absence 
and presence ofl000-fold excess concentration of unlabeled ("cold") 
r-IFN-y to control for nonspecific binding. At various times fol-
lowing incubation at 4°C, or 37°C, duplicate dishes were washed 
4 times w ith DMEM/O.l % BSA and the supernatants pooled and 
counted . The attached washed monolayers were then treated wi th 
3 consecutive solubilization steps utilizing 1 % sodium dodecyl 
sulfate (Na Dod S04) and pooled and counted in a Beckman 
Gamma Counter (70% efficiency) . Nonspecific binding repre-
sented the radioactivity bound to the keratinocytes in the presence 
of excess (lOOO-fold) cold r-IFN-y. Specific binding represents 
the difference between the total and nonspecifi c binding. N on-
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Figure 2. Time and temperature dependence of specific 1251-IFN-y bind-
ing to cultured human keratinocytes. Nonspecific binding was determined 
by adding excess (1000-fold) nonradiolabeled r-IFN-y and was found to 
average 35% of total binding at 37°C and 25% of total binding at 4°C. 
INTERFERON- y I3INDING TO KERA T INOCYTES 133 
Table I. Inhibition of 12sl_Gamma Interferon (IFN-y) 
(100 pmo l) Binding to Keratinocytes by "Cold" Interferons 
Addition 
o 
r-IFN-y (103 pmol) 
r-IFN-y (10· pmol) 
r-IFN-y (10s pmol) 
Murine r-IFN-y (103 pmol) 
Murine r-IFN-y (105 pmol) 
Human r-IFN-t3 (103 pmol) 
Human r-IFN-t3 (10s pmol) 
Specific Binding 
(cpm) 
1520 
1220 
973 
213 
1498 
1511 
1486 
1493 
r-IFN-y = recombinant gamma interferon. 
r- IFN-J3 = recombinant beta interfe ron. 
% Inhibition 
o 
19 
26 
86 
1.5 
< 1 
3 
2 
specific binding averaged 35% of the total binding at 37°C and 
25% of the total binding at 4°C. 
Inhibition of 12sl_IFN_y Binding to Keratinocytes by Un-
labeled r-IFN-y Keratin ocyte monolayers were incubated with 
'2sI_IFN_y (100 pmol) and various concentrations of cold r-IFN-
y or r-IFN-/3 or murine r-IFN- y (103 - lOS pmol), at 37°C for 90 
min, and the binding assay performed as described above 
(Table I) . 
Scatchard Analysis of 12sl_IFN_y Binding to Receptors on 
Keratinocytes Keratinocyte J11 onolayers were incubated with 
increasing concentrations of '2sI_IFN_y (53-526 pmol) at 4°C with 
shaking for 300 min. The nonspecific binding was determined by 
m easuring the binding of the 125I_IFN_y in the presence of 1000-
fold excess cold IFN- y. The resulting data was subj ected to Scat-
chard analysis [8]. The number of receptors per cell on the ke-
ratinocytc mono layers was determined by the following equation: 
Number of (Change in bound) X (6.022 X 1023) 
receptors Free 
Cell - ----(:-K-:-e-r-a-:-ti-.n-o-c-y-te-:-)-- ---
LIter 
The estimated keratinocyte density for this calculation was 1 X 
107 cells/ml. The standard error of the mean for the ligand binding 
studies was approximately 15% . 
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Figure 3. Binding of 125I_IFN_y to keratinocytes at increasing concen-
tration . Semiconfluent keratinocyte monolayers were incubated wi th in-
creasing concentrations of 1251_IFN_y at 4°C for 300 min. The cells were 
then washed and processed as described. Nonspecific binding was deter-
mined in a parallel set of cultures with 1000-fo ld excess unlabeled r-IFN-
y. 
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Figure 4. Sca tchard ana lys is of liga nd binding data from Fig 3. A linea r 
plot was obtained (regression coeffi cient = 0.9). The kD was 1.3 X '10 - 10 
M with 2200 recepto r sitcs/kerat in ocyte. 
RESULTS 
Biologic Activity of 12sI_IFN_y T he retention of biologic ac-
ti vity of th e labeled r-IFN-y recovered followin g radioiodination 
was determined by m easuring the ind uction ofkerati nocyte HLA-
DR expression . Fi gure 1 reveals th at usin g "100" and "300" U / ml 
(based on weight) of r-lFN-y after th e iodination process, ap-
proximately 90% of the biologic activity was retained w hen com-
pared w ith the same amount of non iod inated r-lFN-y. 
Time-Course ofIFN- y Binding 1251_IFN_y bound to specifi c 
receptors on cultured keratin ocytes in a time- and temperature-
dependent fas hion (Fig 2). At 4°C, the stead y state was achieved 
afte r 150-180 min, but at 37°C, no saturation was o bserved after 
5 h incubation. T he lack of saturation at 37°C could be due to 
the internaliza tion of IFN-y [9]. Three different preparations of 
radiolabeled r-I FN-y produced sim ilar values . 
Specificity of IFN-y Binding B inding site co mpetition be-
tween 1251_IFN_y and unl abeled r-IFN-y are shown in Table I. 
The r-I FN-y, but not the r-IFN-f3 or murine r-IFN-y inhibited 
the binding of 1251-IFN-y to the keratinocytes . T he co mpetition 
data indicate that the binding sites are specific for r- IFN-y. 
IFN-y Binding to Keratinocytes and Scatchard Analysis 
Binding data uti lizing in creasin g concentrations of 1251_IFN_y and 
cultured keratinocytes are shown in Fig 3. Saturation of the re-
ceptor was achieved at the hi gher 1251_IFN_y concentrations uti-
lized. Scatchard analys is of the li gand binding data yielded a linea r 
plot (regression coefficient = 0.9) indi ca tin g the presence of a 
single class of binding si tes. The dissociation constant was 1.3 x 
10 - 10 M w ith 2200 receptors/keratinocyte (Fig 4). 
T H E JOU RNAL OF INV ESTIGATIV E DERMATOLOGY 
DISC USSIO N 
T he uti lization of the Bolton-Hun ter reagent prod uced hi gh spe-
cific act ivity radio labeling of r-IFN-y with good retention of 
bio logic activi ty (Fig 1). T he resu ltant hi gh specifi c acti vity io-
di luted r-IFN-y produced liga nd binding results w hich indi cate 
a sin gle class of specifi c high affini ty receptors for lFN-y on 
cultured hum an keratinocytes . The data presented serve to define 
and parti all y chara cterize the IFN-y receptor o n cul tured hum an 
kerat in ocytes. T he pl ateau in bindin g at 4°C at 150 min (Fig 2) 
is similar to previous reports usin g other cell types [1 0,11]. The 
dissociation constant of 1. 3 x IO - 11l M (Figs 3, 4) correlates well 
with our previo us biologic studies [1 2] of th e induction of HLA-
DR and o ther pro teins w ith a half-m ax imal response to r-IFN-y 
between 10- '1 to 10- 10 M. T hu s, w hi le lFN-y induces a w ide 
spectra of bio logic response in keratinocytes [1-5], the binding 
of IFN-y to its cell surface receptor is the first step in all these 
reaction s and the binding data agrees well with these biologic 
responses . 
Tab le II summarizes the previousl y published IFN - y recepto r-
binding charac teristics on both m o use and hum an cell s. As can 
be seen, there is a w ide var iety of reported va lues for hem ato-
poietic and non hen"latopoiet ic cell s. T he current data utilizing r-
IFN-y and cultured human keratinocytes revealed a kD w hich is 
in agreem ent w ith th e more recent li gand-bindin g studies . The 
number of es tim ated receptor sites per keratinocy te (approxi-
mately 2200) is also within the repo rted range as seen in Table 
II. The most recent data utili zing hi g h specific ac ti vity murine r-
IFN- y ind icates a hi gh affinity receptor w hich m ay have been 
missed in ea rl ier studies utilizing iodinated IFN-y o fl ower specifi c 
acti vit y at signifi cantly higher IFN-y concentration . [6]. In this 
rega rd , the concentration ran ge of biologic responses eli cited by 
r-IFN-y indica te that only approxim ately 5% occupancy of high 
affinity sites is required for 50% m aximal induction o f murine la 
antigen expression [6]. -
T here have been conflictin g reports detailing the ability o fIFN-
{3 to co mpete for IFN-y receptor sites. Two studies documented 
cross-reactivity using nonreco mbin ant IFN-{3 [9 ,11] w hereas 3 
other studies failed to demonstrate signi ficant cross-reactivity with 
either nonreco mbin ant or recombinant IFN-{3 [6,11, 18] . T he lack 
of cross-reactivity between murin e and hum an IFN-y (Table I) 
suggests that the species specific ity of the biologic activity ofIF Ns 
m ay res ide at the receptor level. 
T he presence of high affll1ity receptors fo r IFN-y on cultured 
keratinocytes provides additional support for the no~ion that lym-
phocy te prod ucts can biochemi call y interact w ith keratinocytes 
[1 9]. Thus, not o nly has nature provided the skin with unique 
immunocompetent lympho id cells, but has endowed the kerati-
nocyte w ith specifi c receptors for products of lym phocytes as-
surin g the reception of appro priate immunologic signals [20]. 
Sin ce the ability of r-IFN-y to induce HLA-DR synthesis in ke-
ratinocy tes continues to be of interest to in ves ti ga tive skin biol-
ogists [21], further work o n the modulation of keratinocyte 
Table II. C haracteristics of the Gam m a Interferon Recepto r 
Investiga tors Cell Type kD(M) Receptors/Cell 
Anderson et al 11 01 Human fibroblast 1.5 X 10- 10 2,400 
Sarka r et al [1 3] WISH cel ls 7.0 X 10 - " 50,000-70,000 
Cclada et al 1141 Murine macrophagcs S.3 x 10- 9 15,200 
Littman et al [1 51 Daudi cells 3.7 X 10 - 10 13,000 
HeLa cells 6.3 x IO - IU 5,000 
Finbloom et al ll 1] Human monocytcs 2.5 X 10- 10 4,000 
Orchansky et al 11 61 Human monocytes 6.S X 10- 9 2,400 (mu ltip le sites) 
WISH cells 1.4 x 10- 9 20,100 
Rashidbaigi ct al [1 7] U-937 cel ls 1.5 X 10 - 10 1,SOO 
Aiyer et al 16] Murine macrophages 9.1 X 10 - 11 500 (high affinity) 
2.7 X 10- 9 4,400 (low affinity) 
Current stud y Human keratinocytcs 1. 3 X 10- 10 2,200 
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IFN-y receptors m ay prov ide new insig ht into ly mphocyte-ke-
ratin ocy te in teractions and liga nd-binding techniques will allow 
guantita tio n of keratinocyte IFN-y receptors in both n o rmal and 
inflam ed skin. 
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